Thursday, September 29, 2022


Biotechnology News Magazine

Global Insomnia Clinical Trial Pipeline Report 2021

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 27, 2021

Global Insomnia Clinical Trial Pipeline Highlights – 2021″ provides the most up-to-date information on key pipeline products in the global Insomnia market. It covers emerging therapies for Insomnia in active clinical development stages including early and late-stage clinical trials.

The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Insomnia pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Insomnia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.


The report provides Insomnia pipeline products by the company.

Short-term Launch Highlights:

Find out which Insomnia pipeline products will be launched in the US and Ex-US till 2025.


  • Insomnia phase 3 clinical trial pipeline products
  • Insomnia phase 2 clinical trial pipeline products
  • Insomnia phase 1 clinical trial pipeline products
  • Insomnia preclinical research pipeline products
  • Insomnia discovery stage pipeline products
  • Insomnia pipeline products short-term launch highlights

Key Topics Covered:

1. Insomnia Pipeline by Stages

2. Insomnia Phase 3 Clinical Trial Insights

3. Insomnia Phase 2 Clinical Trial Insights

4. Insomnia Phase 1 Clinical Trial Insights

5. Insomnia Preclinical Research Insights

6. Insomnia Discovery Stage Insights

7. Appendix

8. Research Methodology

Countries Covered

  • Global
  • Europe
  • US
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Japan

For more information about this report visit here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine